Anti-β-Catenin antibody
Description
Application Data
Description
-
Recognises β-Catenin a key protein in the Wnt signalling pathway, involved in cancer progression
Application Data
-
Anti-β-Catenin antibody (crb2005237) (1μg/ml)
Western blot analysis of whole cell extract human embryonic kidney cells HEK293 cells (30µg) and human prostate cancer CWR cells (30µg) .
Lane 1: HEK293 (30ug)
Lane 2: CWR (30ug)
| Catalogue number | crb2005237 |
|---|---|
| Antibody | Anti-β-Catenin antibody |
| Antigen Peptide | KLH conjugated synthetic peptide crb1200480e |
| Protein ID | UniProtKB - P35222 |
| Aliases | Beta-Catenin, Catenin beta-1,CTNNB |
| Cross-Reactivity | Human, rat, mouse, chicken, rhesus macaque |
| Target Protein Species | Human, rat, mouse, chicken, rhesus macaque |
| Host Species | Rabbit |
| Antibody Type | Polyclonal |
| Concentration | 0.4 mg/ml |
| Validation | 1:1000 (ELISA), 1ug/ml (WB) |
| Target | β-Catenin |
| Storage Stabilisers | This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles. |
| Disease Area | Cancer, DNA Damage, apoptosis, transcription, cell cycle, signal transduction |
| Specificity | Protein |
| Storage | This material is supplied in PBS containing 0.01% sodium azide and 1% trehalose. The product should be stored at +4°C for short term storage and -20°C for long term storage. Avoid repeated freeze/ thaw cycles. |
| References | Shang et al., (2017). The regulation of β-catenin activity and function in cancer: therapeutic opportunities. Oncotarget. 8(20): 33972–33989. PMID: 28430641 |
β-Catenin is a multifunctional protein that acts both as a transcriptional co-regulator and an adaptor protein for intracellular adhesion and is a vital component of the Wnt signalling pathway, an evolutionarily conserved pathway crucially involved in embryonic development and tissue homeostasis.
Wnt signalling pathway is the main regulator of β-catenin, when the pathway is not active, β-catenin is kept at a low level by the ubiquitin proteasome system (UPS). Following nuclear translocation via activation of the Wnt signalling pathway, β-catenin is thought to form a transcriptional complex with DNA binding proteins such as TCF/LEF, p300/CBP to help fulfil its role as a transcriptional activator.
Aberrant activation of Wnt signalling results in the accumulation of β-catenin in the nucleus and promotes the transcription of many oncogenes such as c-Myc and CyclinD-1. Indeed, once in the nucleus, β-catenin binds to several nuclear proteins involved in tumour development or progression such as p300/CBP, TATA-box binding protein (TBP), Pontin52, Reptin52, Brg-1, MUC1-C, SOX10, p68/p72, FOXM1, yes-associated protein 1 (YAP1) and FBW1. Over-expression of β-Catenin has been linked to various diseases including colon cancer, hepatocellular carcinoma, pancreatic cancer, lung cancer, skin cancer breast cancer and ovarian cancer.